Superpower peptides available for pre-order. Get first access.
Not FDA-approved
Brain & sleep
Selank
Selank is a synthetic peptide approved for anxiety in Russia but not by the FDA. Learn how it is proposed to work and how limited the human evidence is.
- Reviewed by
- William Maish, MD MBA MPH, Clinical Product Lead
- Published
- April 18, 2026
- Last updated
- October 5, 2026
Key takeaway
Selank is a synthetic anxiolytic peptide developed in Russia, where it is approved for anxiety, and sold elsewhere on the "research peptide" market for anxiety and focus. The human evidence is limited to small, mostly Russian-language studies that have not been independently replicated to Western regulatory standards. As of 2026 it is not FDA-approved.
What is selank?
Selank, sometimes shorthanded as TP-7, is a synthetic seven-amino acid peptide, a stabilized analog of a natural peptide called tuftsin. It was developed by Russian research institutes and is approved in Russia as an anti-anxiety agent. Outside Russia it is sold through wellness and "research peptide" channels for anxiety and focus, and it is not an approved medicine in the United States.
How does it work?
Selank is proposed to have calming effects by modulating the brain's enkephalin and GABA systems, influencing serotonin metabolism, and affecting levels of a nerve-growth signal called BDNF. These mechanisms come mainly from animal and laboratory work. This describes the proposed mechanism, separate from demonstrated benefit in people.
Is it FDA-approved?
No. Selank is not approved by the FDA. It is approved as an anxiolytic in Russia. In the United States it is sold only as a "research chemical," is not on FDA compounding lists, and was not among the peptides reviewed favorably at the 2026 FDA compounding advisory meetings.
What does the research show?
There is some human evidence, but of limited quality. Small Russian studies have reported anxiety-reducing effects, including a comparison with a benzodiazepine and a study1 suggesting selank reduced benzodiazepine side effects. These trials are generally:
- Small
- Single-country
- Often conducted by the developing institutions
- Published in Russian
- Not independently replicated
An analytical review2 notes that such peptides have not completed clinical trials to Western regulatory standards. The evidence does not establish efficacy by those standards.
What is the difference between selank and semax?
Selank and semax are both synthetic seven-amino acid peptides developed by Russian research institutes, and the main difference is the natural molecule each is based on and the use each is approved for in Russia. Their proposed mechanisms are also described differently.
| Attribute | Selank | Semax |
| Based on | Tuftsin, a natural immune-modulating peptide (selank is a stabilized analog) | A fragment of the hormone ACTH |
| Approved in Russia for | Anti-anxiety agent | Stroke and cognitive and neurological conditions |
| Proposed mechanism | Acts on the brain's enkephalin and GABA systems and on serotonin metabolism | Raises nerve-growth signals such as BDNF and NGF3 |
| FDA status | Not FDA-approved | Not FDA-approved |
| FDA compounding advisory review | Not among the peptides reviewed favorably | Non-binding favorable vote in July 2026 toward allowing it to be compounded, which FDA staff opposed4 |
Both mechanism descriptions come mainly from animal and laboratory work, and neither has been shown to produce a benefit in people. The advisory vote is the one U.S. regulatory difference, and an advisory vote is only a recommendation; it does not make semax approved.
The human evidence for both is limited in the same way: small, mostly Russian studies, often run by the developing institutions and not independently replicated. An analytical review2 notes that such peptides have not completed clinical trials to Western regulatory standards. The evidence does not establish that either one works or that one works better than the other.
Sources: a Russian clinical study of selank (Medvedev et al., Zhurnal Nevrologii i Psikhiatrii, 2015, DOI: 10.17116/jnevro20151156133-401) and an analytical review of research peptides (Esposito et al., Drug Testing and Analysis, 2020, DOI: 10.1002/dta.27172), indexed on PubMed. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.